

The journal has had 20 points in Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553. Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences). Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Uniwersytecki Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).
© The Authors 2024:
This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Toruń, Poland
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike (<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 15.02.2024. Revised: 05.04.2024. Accepted: 08.04.2024. Published: 11.04.2024.

PECULIARITIES OF METABOLIC AND AUTONOMIC-ENDOCRINE ACCOMPANIMENTS OF URATE-LOSING/RETAINING KIDNEYS

Volodymyr S. Ishchenko¹, Walery Zukow²

¹International Humanitarian University, Odesa, Ukraine ischenkovov@gmail.com

²Nicolaus Copernicus University, Toruń, Poland w.zukow@wp.pl

Abstract

Background. This publication initiates the project "Neuro-endocrine regulation of the clearance of nitrogenous metabolites". The first stage of project implementation is the clarification of peculiarities of metabolic and neuro-endocrine accompaniments of urate-losing and urate-retaining kidneys. **Materials and Methods.** The object of observations were patients with chronic pyelonephritis in the phase of remission (34 males aged 23-70 years and 10 females aged 33-76 years). Testing was performed twice - on admission and after 7-10 days of standard balneotherapy on Truskavets Spa. The battery of tests was created in line with concepts functional-metabolic continuum and NEI network. The content of nitrogenous metabolites and electrolytes was determined in daily urine and blood serum. In addition, indicators of the lipoprotein spectrum and lipids peroxidation, as well as the level of the main adaptation hormones, were determined in the blood. The state of the autonomic nervous system was assessed by the HRV method. **Results.** In 63.6% of cases, the renal clearance of uric acid was within the classical norm ($\pm 2\sigma$), in 12.5% it was moderately reduced, but in the remaining cases it was increased, including drastically in 3 cases. The method of discriminant analysis revealed 20 parameters, according to the totality of which all 4 clusters of uric acid clearance clearly differ from each other (classification accuracy 100%). **Conclusion.** Constitutionally distinct types of uric acid metabolism (euricosis, urate-losing and urate-retaining kidneys) are characterized by specific constellations of metabolic and autonomic-endocrine parameters.

Keywords: uric acid clearance, urine and serum metabolites and electrolytes, lipids peroxidation, HRV, adaptation hormones, chronic pyelonephritis.

INTRODUCTION

A 100-year history of basic and clinical studies supports UA being a direct risk factor for chronic kidney disease (CKD). Nevertheless, controversy exists over the causal role of UA in the development or exacerbation of CKD, with conflicting results being produced in various studies. Although many nephrologists currently treat asymptomatic patients with hyperuricemia, there is no consensus on the appropriateness of such a treatment approach. Furthermore, hypouricemia has been shown to increase the risk for deterioration of renal function, making it more difficult to set a target range for the optimal serum UA level. In the CARES trial, all-cause and cardiovascular mortality were higher in the febuxostat group than in the allopurinol group, even though patients receiving febuxostat had lower serum UA levels. The higher mortality associated with this more intense UA-lowering therapy is consistent with the U-shaped association between UA and mortality proposed in some observational studies. Because UA is the most abundant antioxidant in plasma, strategies to increase UA are ongoing in clinical trials of patients with neurological diseases. Further research is needed to assess the safety of lowering serum UA to specific thresholds to produce safe guidelines. Optimal serum UA levels should be defined at both upper and lower limits, for men and women, and in patients with and without CVD or CKD. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that UA has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress [29]. Elevated serum urate concentration is the primary cause of gout. Understanding the processes that affect serum urate concentration is important for understanding the etiology of gout and thereby understanding treatment [19].

Back in 1989, Karve MD et al [21] put forward the concept of the "urate-retaining" and "urate-losing" kidney as a reflection of constitutionally different types of uric acid metabolism, due to the heterogeneity of filtration-reabsorption mechanisms and endocrine functions of the kidneys, which leads to hyperuricemia in some individuals or hypouricemia in others. However, judging by the lack of subsequent publications on the subject, the concept has been largely ignored by the scientific community. Only in 2004, this concept attracted the attention of Ivassivka SV et al [20]. Among 200 patients of the Truskavets' spa, the authors found uric acid clearance in the range of 50÷150% of the average norm in 79, while 103 were diagnosed with "urate-losing" kidneys and only 18 with "urate-retaining" kidneys. However, the case did not go beyond the establishment of different types of uric acid exchange.

Given the known wide spectrum of physiological activity of uric acid [4,6,10,24,27], we set ourselves the goal of identifying peculiarities of metabolic and neuro-endocrine accompaniments of urate-losing and urate-retaining kidneys.

MATERIALS AND METHODS

The object of observations were patients with chronic pyelonephritis in the phase of remission (34 males aged 23-70 years and 10 females aged 33-76 years). Testing was performed twice - on admission and after 7-10 days of standard balneotherapy on Truskavets Spa (drinking of Naftussya bioactive water, applications of ozokerite, mineral pools) [28,30].

The battery of tests was created in line with concepts functional-metabolic continuum [12,18] and NEI network [15,31]. It is known about the existence of close functional link between adequate working kidney nephrons and bone metabolism. Focused monitoring of renal function is able to provide 482 substantial assistance in the organization of preventive measures against latently emerging osteoporosis [13]. Activation of lipids peroxidation is known to inhibit glomerular filtration, whereas antioxidants prevent this [7,14,16,34]. These facts became the basis for determining calcitonin, PTH and parameters of lipids peroxidation. The known connections of urinary uric acid with the parameters of the autonomic nervous and endocrine systems [4,24] became the basis for determining the parameters of HRV and adaptation hormones.

Daily urine was collected on the eve, in which was determined the concentration of uric acid (estimated by uricase method), creatinine (by Jaffe's color reaction by Popper's method) and urea (urease method by reaction with phenolhypochlorite) as well as electrolytes: calcium (by reaction with arsenase III), magnesium (by reaction with colgamite), phosphates (phosphate-molybdate method), chloride (mercury-rhodanidine method), sodium and potassium (flamming photometry). Urine lytogenicity index calculated by the Tiselius' HS [33] formula modified by Flyunt VR et al [8]: Lytogenicity = $(UA \cdot Ca/Mg \cdot Creatinine)^{0.25}$.

The same metabolic parameters were determined in serum as well as total cholesterol and content of it in composition of HD, LD and VLD lipoproteins) [11]; diene conjugates (spectrophotometry of heptane phase of lipids extract) [9]) and malondialdehyde (test with thiobarbiture acid) [2], as well as the activity of antioxidant enzymes: catalase serum (by the speed of decomposition hydrogen peroxide) [25] and superoxide dismutase erythrocytes (by the degree of inhibition of nitroblue tetrazolium recovery in the presence of N-methylphenazone metasulfate and NADH) [5,26]. The analysis carried out according to instructions [11] with the use of flaming spectrophotometer "CФ-46", analyzers "Reflotron" (BRD) and "Pointe-180" (USA) and corresponding sets of reagents.

In addition, we determined serum levels of main adaptation hormones such as Cortisol, Aldosterone, Testosterone, Triiodothyronine as well as Calcitonin and PTH (by the ELISA with the use of analyzer "RT-2100C" and corresponding sets of reagents from "Алкор Био", XEMA Co, Ltd and DRG International Inc). Systolic (Ps) and diastolic (Pd) blood pressure was measured (tonometer "Omron M4-I", Netherlands) in a sitting position three times in a row followed by the calculation of Ps2/Ps1, Ps3/Ps1, Pd2/Pd1, and Pd3/Pd2 ratios [32]. The good old Stange's and Genchi's tests were carried out on occasion [3].

To assess the parameters of heart rate variability (HRV), recorded electrocardiogram during 7 min in II lead (hardware-software complex "CardioLab+HRV" produced by "KhAI-Medica", Kharkiv, Ukraine). For further analysis the following parameters HRV were selected. Temporal parameters (Time Domain Methods): heart rate (HR), the standard deviation of all NN intervals (SDNN), the square root of the mean of the sum of the squares of differences between adjacent NN intervals (RMSSD), the percent of interval differences of successive NN intervals greater than 50 ms (pNN₅₀), triangular index (TNN). Spectral parameters (Frequency Domain Methods): power spectral density (PSD) bands of HRV: high-frequency (HF, range 0,4÷0,15 Hz), low-frequency (LF, range 0,15÷0,04 Hz), very low-frequency (VLF, range 0,04÷0,015 Hz) and ultralow-frequency (ULF, range 0,015÷0,003 Hz). We calculated classical indexes: LF/HF, LFnu=100%•LF/(LF+HF), Centralization Index (VLF+LF)/HF [15,24,31].

Normal (reference) values of variables are taken from the instructions and/or database of our group [11,22,31]. For statistical analysis used the software package "Microsoft Excell" and "Statistica 6.4 StatSoft Inc" (Tulsa, OK, USA).

RESULTS

First of all, a complete lack of correlation was found between both components of clearance - uricosuria and uricemia (Fig. 1). That is, they are related to clearance independently (Fig. 2).




Fig. 1. Absence of correlation between uricemia and uricosuria

$$Z(\pm 1,72) = 9,43(\pm 0,90) - 30,75(\pm 2,22) \cdot X + 2,45(\pm 0,12) \cdot Y$$

$R=0,936$; $R^2=0,877$; $Adj\ R^2=0,874$; $F_{(2,9)}=302$; $p<10^{-6}$




Fig. 2. Quadratic surface of relationship between uricemia (X-line), uricosuria (Y-line) and uric acid clearance (Z-line)

At the same time, uricosuria determines the clearance of uric acid by 61% (Fig. 3), and uricemia by only 37% (Fig. 4).




Fig. 3. Scatterplot of correlation between uricosuria (X-line) and uric acid clearance (Y-line)




Fig. 4. Scatterplot of correlation between uricemia (X-line) and uric acid clearance (Y-line)

Given the significant gender differences in the reference values of uricemia [20,22,24], they, as well as the norms of uricosuria and clearance, were recalculated on Z-scores (normalized). At the next stage, the sample was divided into quantitative and qualitative clusters (Fig. 5).

In 56 cases (45 men and 11 women), the values of renal clearance of uric acid were in the classical normal range: $-1.97\sigma \div +1.74\sigma$.

In 11 cases (5 men and 6 women), reduced clearance ($-2.01\sigma \div -3.28\sigma$), that is, a urate-retaining kidney, was established. Instead, 18 men and 3 women were diagnosed with a urate-losing kidney. In view of the "jumping" values of the clearance falling into the eyes in three cases (Figs. 3-4), they were allocated to a separate cluster. By the way, the problem of dropped values was considered by our group in a recent article, in which it was demonstrated that they are accompanied by anomalous deviations of a number of other parameters, that is, they are carriers of unique information, and not artifacts that should be discarded [17]. Spoiler: this will be confirmed in this article.




Fig. 5. Clusters of uric acid clearance

Screening of the registered parameters, previously recalculated on Z-scores [30], revealed those whose patterns to one degree or another are similar to the pattern of renal clearance of uric acid (Fig. 6, see also Table 5).

The constellation of uricosuria, diuresis, excretion of urea and calcium, as well as LF band HRV, were found to be the most similar, the levels of which were significantly reduced in cases of urate-retaining kidney, normal in cases of euuricosis, increased in cases of urate-losing kidney, and abnormally high in three separate cases. On the other hand, the constellation of 5 parameters of the second pattern (blood levels of uric acid, sodium, chloride, catalase, as well as Stange's test) is almost a mirror image. The remaining patterns are only partially similar or mirror the pattern of uric acid clearance.




Fig. 6. Patterns of neuro-endocrine-metabolic accompaniments of four clusters of uric acid clearance. Under each pattern the number of variables is indicated

Discriminant analysis (method forward stepwise) [23] was used to identify the specific accompaniment of uric acid clearance. The discriminant model includes (Tables 1 and 2), in addition to **clearance, uricosuria and uricemia** by definition, 8 **autonomic-endocrine**, 2 **lipids peroxydation**, 9 **metabolic** variables, as well as Stange's test (spoiler: neural marker).

Table 1. Summary of discriminant function analysis

Step 23, N of vars in model: 23; Grouping: 4 grp; Wilks' Λ : 0,009; appro. $F_{(69,2)}=10,4$; $p<10^{-6}$

| Variables currently in the model (Mean±SE) | Clusters of Uric Acid Clearance (M/F) | | | | Parameters of Wilks' Statistics | | | | | Norm Cv |
|--|---------------------------------------|---------------|--------------|--------------|---------------------------------|--------------------|------------------|-----------|-----------|---------------|
| | C++ (2/1) | C+ (16/2) | Cn (45/11) | C- (5/6) | Wilks Λ | Parti-al Λ | F-re-move (3,62) | p-level | Tolerance | |
| Uric Acid Clearance, mL/min | 27,0 2,2 | 13,33 0,35 | 7,68 0,27 | 3,65 0,22 | 0,049 | 0,182 | 93,19 | 10^{-6} | 0,101 | 7,94 0,215 |
| Uricosuria, mM/24 h | 6,56 0,37 | 5,40 0,29 | 3,57 0,14 | 1,99 0,11 | 0,029 | 0,311 | 45,80 | 10^{-6} | 0,074 | 3,00 0,250 |
| Uricemia, μ M/L | 170 10 | 282 13 | 329 10 | 386 22 | 0,027 | 0,324 | 43,12 | 10^{-6} | 0,095 | 263 0,181 |
| RMSSD HRV, msec | 40,3 7,2 | 30,5 4,1 | 28,4 2,4 | 23,8 3,3 | 0,010 | 0,849 | 3,67 | 0,017 | 0,032 | 28,8 0,486 |
| pNN ₅₀ HRV, % | 16,5 6,0 | 10,7 2,8 | 9,8 1,8 | 3,2 1,1 | 0,011 | 0,824 | 4,41 | 0,007 | 0,042 | 9,0 0,820 |

| | | | | | | | | | | |
|--|---------------|---------------|---------------|---------------|-------|-------|------|-------|-------|----------------|
| Total Power HRV, msec² | 6071 1608 | 2647 440 | 2544 282 | 1937 249 | 0,010 | 0,895 | 2,42 | 0,074 | 0,015 | 2379 0,402 |
| ULF band HRV, msec² | 20 13 | 118 41 | 78 15 | 148 32 | 0,010 | 0,897 | 2,37 | 0,079 | 0,406 | 122 0,892 |
| VLF band HRV, msec² | 2584 652 | 1085 173 | 1117 109 | 1145 182 | 0,010 | 0,870 | 3,10 | 0,033 | 0,065 | 1250 0,572 |
| LF band HRV, msec² | 2785 736 | 1081 202 | 861 105 | 393 80 | 0,010 | 0,906 | 2,14 | 0,105 | 0,051 | 625 0,482 |
| LFnu HRV, % | 81,8 5,0 | 72,3 4,1 | 71,1 2,2 | 64,5 5,1 | 0,010 | 0,868 | 3,14 | 0,032 | 0,232 | 64,2 0,201 |
| Calcitonin normalized, Z | -0,95 0,07 | -0,64 0,18 | -0,66 0,14 | -0,43 0,23 | 0,011 | 0,809 | 4,89 | 0,004 | 0,593 | 0 |
| Catalase, $\mu\text{M/L}\cdot\text{h}$ | 37 10 | 88 11 | 123 7 | 134 20 | 0,010 | 0,904 | 2,19 | 0,098 | 0,289 | 125 0,458 |
| Superoxide dismutase, U/mL | 53 4 | 63 6 | 78 3 | 70 9 | 0,011 | 0,840 | 3,94 | 0,012 | 0,248 | 62 0,286 |
| Urea Serum, mM/L | 7,27 1,00 | 6,27 0,38 | 5,97 0,12 | 5,27 0,26 | 0,012 | 0,758 | 6,61 | 0,001 | 0,543 | 5,60 0,178 |
| Calcium Serum, mM/L | 2,12 0,08 | 2,20 0,05 | 2,18 0,02 | 2,30 0,06 | 0,009 | 0,952 | 1,04 | 0,382 | 0,515 | 2,30 0,065 |
| Phosphates Serum, mM/L | 0,98 0,11 | 1,01 0,05 | 1,00 0,02 | 1,14 0,08 | 0,009 | 0,937 | 1,39 | 0,254 | 0,442 | 1,20 0,167 |
| Potassium Serum, mM/L | 3,95 0,38 | 4,50 0,11 | 4,35 0,07 | 4,18 0,17 | 0,010 | 0,892 | 2,50 | 0,068 | 0,599 | 4,55 0,104 |
| Diuresis, L/24h | 2,87 0,07 | 2,52 0,15 | 1,88 0,08 | 1,41 0,20 | 0,010 | 0,924 | 1,70 | 0,177 | 0,208 | 1,40 0,274 |
| Chloride Excretion mM/24h | 316 49 | 263 23 | 212 13 | 186 34 | 0,011 | 0,822 | 4,48 | 0,007 | 0,341 | 167,5 0,172 |
| Phosphates Excretion, mM/24h | 27,4 7,4 | 32,0 3,6 | 23,0 2,1 | 14,1 2,8 | 0,009 | 0,939 | 1,35 | 0,266 | 0,449 | 25,2 0,294 |
| Creatininuria, mM/24h | 8,96 0,80 | 8,49 0,70 | 8,20 0,55 | 6,63 0,88 | 0,010 | 0,915 | 1,92 | 0,136 | 0,274 | 11,0 0,300 |
| (U•Ca)/(Cr•Mg)^{0,25} Lytogenicity Urine | 1,00 0,04 | 0,94 0,04 | 0,84 0,02 | 0,72 0,03 | 0,010 | 0,915 | 1,92 | 0,136 | 0,290 | 0,73 0,255 |
| Stange's test, sec | 47 3 | 56 4 | 61 2 | 64 4 | 0,009 | 0,947 | 1,15 | 0,337 | 0,621 | 50 0,200 |

Table 2. Summary of forward stepwise analysis

| Variables currently in the model | F to enter | p-level | Δ | F-value | p-level |
|--|------------|-----------|----------|---------|-----------|
| Uric Acid Clearance, mL/min | 160 | 10^{-6} | 0,149 | 160 | 10^{-6} |
| Uricosuria, mM/24 h | 8,63 | 10^{-4} | 0,114 | 54,4 | 10^{-6} |
| Uricemia, $\mu\text{M/L}$ | 33,3 | 10^{-6} | 0,051 | 53,1 | 10^{-6} |
| Calcitonin normalized by sex, Z | 3,09 | 0,032 | 0,046 | 39,4 | 10^{-6} |
| (UA•Ca)/(Cr•Mg)^{0,25} Lytogenicity | 3,35 | 0,023 | 0,041 | 32,2 | 10^{-6} |
| Phosphates Excretion, mM/24h | 3,32 | 0,024 | 0,036 | 27,8 | 10^{-6} |
| Urea Serum, mM/L | 3,39 | 0,022 | 0,032 | 24,7 | 10^{-6} |
| Superoxide dismutase, U/mL | 2,76 | 0,048 | 0,029 | 22,3 | 10^{-6} |
| VLF band HRV, msec² | 2,47 | 0,069 | 0,026 | 20,4 | 10^{-6} |
| Chloride Excretion mM/24h | 2,05 | 0,115 | 0,024 | 18,7 | 10^{-6} |
| ULF band HRV, msec² | 1,95 | 0,129 | 0,022 | 17,4 | 10^{-6} |
| Total Power HRV, msec² | 1,75 | 0,165 | 0,021 | 16,2 | 10^{-6} |
| RMSSD HRV, msec | 2,24 | 0,091 | 0,019 | 15,3 | 10^{-6} |
| pNN₅₀ HRV, % | 4,25 | 0,008 | 0,016 | 15,1 | 10^{-6} |
| Stange's test, sec | 1,84 | 0,148 | 0,015 | 14,4 | 10^{-6} |
| LFnu HRV, % | 2,21 | 0,095 | 0,014 | 13,8 | 10^{-6} |

| | | | | | |
|--|------|-------|-------|------|-----------|
| Potassium Serum, mM/L | 1,50 | 0,222 | 0,013 | 13,2 | 10^{-6} |
| Catalase, μM/L•h | 1,74 | 0,168 | 0,012 | 12,7 | 10^{-6} |
| Creatininuria, mM/24h | 1,27 | 0,293 | 0,011 | 12,1 | 10^{-6} |
| Diuresis, L/24h | 1,64 | 0,188 | 0,011 | 11,7 | 10^{-6} |
| LF band HRV, msec² | 1,55 | 0,211 | 0,010 | 11,3 | 10^{-6} |
| Phosphates Serum, mM/L | 1,18 | 0,325 | 0,009 | 10,8 | 10^{-6} |
| Calcium Serum, mM/L | 1,04 | 0,382 | 0,009 | 10,4 | 10^{-6} |

Instead, some parameters, despite their obvious recognition ability, were outside the discriminant model, apparently due to duplication/redundancy of information (Table 3).

Table 3. Variables currently not in the model

| Variables (Mean \pm SE) | Clusters of Uric Acid Clearance (M/F) | | | | Parameters of Wilks' Statistics | | | | | Norm Cv |
|---|--|----------------|----------------|----------------|---------------------------------|------------------------|---------------|-------------|----------------|----------------|
| | C++ (2/1) | C+ (16/2) | Cn (45/11) | C- (5/6) | Wilks Λ | Parti- al Λ | F to enter | p- level | Tole- rancy | |
| TNN HRV, units | 15,6 2,4 | 11,1 0,9 | 10,9 0,5 | 9,7 0,85 | 0,009 | 0,957 | 0,91 | 0,442 | 0,176 | 11,2 0,217 |
| SDNN HRV, msec | 79 11 | 48 4 | 47 3 | 44 3 | 0,009 | 0,985 | 0,32 | 0,813 | 0,040 | 56,2 0,516 |
| PTH, pM/L | 4,54 0,43 | 4,34 0,24 | 3,73 0,15 | 2,94 0,33 | 0,009 | 0,971 | 0,61 | 0,610 | 0,083 | 3,75 0,230 |
| Aldosterone, pM/L | 232 5 | 221 5 | 227 4 | 239 4 | 0,009 | 0,974 | 0,54 | 0,654 | 0,219 | 238 0,154 |
| BP systolic, mmHg | 150,1 2,1 | 146,8 4,6 | 135,6 2,3 | 143,6 7,0 | 0,009 | 0,994 | 0,12 | 0,946 | 0,056 | 124,5 0,122 |
| BP diastolic, mmHg | 95,2 4,4 | 87,8 2,9 | 81,2 1,2 | 80,3 2,5 | 0,009 | 0,962 | 0,79 | 0,502 | 0,442 | 79,0 0,083 |
| Ps2/Ps1 Ratio | 0,899 0,041 | 0,931 0,016 | 0,973 0,013 | 0,957 0,009 | 0,009 | 0,984 | 0,34 | 0,796 | 0,652 | 0,964 0,051 |
| Pd2/Pd1 Ratio | 1,013 0,019 | 1,010 0,015 | 0,994 0,010 | 0,983 0,021 | 0,009 | 0,977 | 0,49 | 0,693 | 0,661 | 0,965 0,051 |
| Pd3/Pd1 Ratio | 1,045 0,036 | 1,029 0,011 | 0,996 0,008 | 1,008 0,009 | 0,009 | 0,989 | 0,23 | 0,873 | 0,684 | 0,971 0,041 |
| Diene conjugates, E²³²/mL | 1,83 0,01 | 1,67 0,04 | 1,51 0,02 | 1,50 0,07 | 0,009 | 0,977 | 0,49 | 0,691 | 0,059 | 1,90 0,279 |
| Chloride Serum, mM/L | 88,1 3,9 | 99,5 1,5 | 102,9 0,8 | 105,9 1,6 | 0,009 | 0,993 | 0,15 | 0,932 | 0,512 | 101,5 0,032 |
| Sodium Serum, mM/L | 125,8 4,9 | 140,0 1,9 | 144,3 1,1 | 148,0 1,9 | 0,009 | 0,976 | 0,49 | 0,690 | 0,367 | 145 0,034 |
| Sodium Excretion, mM/24h | 303 44 | 246 21 | 206 11 | 176 31 | 0,009 | 0,972 | 0,59 | 0,623 | 0,043 | 154 0,211 |
| Calcium Excretion, mM/24h | 8,22 1,20 | 6,24 0,72 | 4,84 0,39 | 3,45 0,94 | 0,009 | 0,966 | 0,72 | 0,546 | 0,259 | 4,38 0,214 |
| Magnesium Excretion, mM/24h | 6,11 0,83 | 5,46 0,46 | 4,49 0,26 | 3,72 0,51 | 0,009 | 0,983 | 0,36 | 0,784 | 0,302 | 4,10 0,266 |
| Potassium Excretion, mM/24h | 113 8 | 80 8 | 68 4 | 70 15 | 0,009 | 0,975 | 0,51 | 0,675 | 0,284 | 65 0,269 |
| Urea Excretion, mM/24h | 863 86 | 711 53 | 546 27 | 350 45 | 0,009 | 0,966 | 0,72 | 0,543 | 0,151 | 458 0,186 |

Following the algorithm [15,30,31], we transform the 23-dimensional space of discriminant variables into the 3-dimensional space of canonical roots. The canonical correlation coefficient for the first root is 0,965 (Wilks' $\Lambda=0,009$; $\chi^2_{(69)}=347$; $p<10^{-6}$), for the

second 0,898 (Wilks' $\Lambda=0,131$; $\chi^2_{(44)}=150$; $p<10^{-6}$); for the third 0,572 (Wilks' $\Lambda=0,673$; $\chi^2_{(21)}=29$; $p=0,110$). The major root contains 74,7% of the discriminant possibilities, the minor – 22,6%, the last – 2,7% only.

Calculating the values of the discriminant roots for each person based on raw coefficients and constants (Table 4) allows to visualize each patient in the information space of these roots (Fig. 7).

Table 4. Standardized and raw coefficients and constants for variables


| Coefficients | Standardized | | | Raw | | |
|---|--------------|--------|------------------------|---------|---------|---------|
| | Variables | Root 1 | Root 2 | Root 3 | Root 1 | Root 2 |
| Uric Acid Clearance, mL/min | -2,387 | 1,851 | -0,112 | -1,258 | 0,975 | -0,059 |
| Uricosuria, mM/24 h | 1,894 | -2,706 | 0,615 | 1,828 | -2,612 | 0,594 |
| Uricemia, $\mu\text{M/L}$ | -1,127 | 2,708 | -0,394 | -0,016 | 0,038 | -0,006 |
| Calcitonin normalized by sex, Z | 0,585 | 0,014 | 0,105 | 0,669 | 0,016 | 0,120 |
| $(\text{UA} \cdot \text{Ca})/(\text{Cr} \cdot \text{Mg})^{0,25}$ Lytogenicity | -0,321 | 0,010 | -0,774 | -2,298 | 0,073 | -5,545 |
| Phosphates Excretion, mM/24h | -0,349 | -0,161 | 0,084 | -0,023 | -0,011 | 0,006 |
| Urea Serum, mM/L | 0,073 | -0,711 | -0,323 | 0,066 | -0,643 | -0,292 |
| Superoxide dismutase, U/mL | 0,568 | -0,541 | -0,576 | 0,024 | -0,023 | -0,024 |
| VLF band HRV, msec ² | -0,663 | 0,989 | 1,577 | -0,0008 | 0,0013 | 0,0020 |
| Chloride Excretion mM/24h | 0,710 | -0,238 | -0,141 | 0,0073 | -0,0025 | -0,0015 |
| ULF band HRV, msec ² | -0,098 | -0,304 | 0,722 | -0,0008 | -0,0024 | 0,0057 |
| Total Power HRV, msec ² | 1,060 | -0,602 | -4,241 | 0,0005 | -0,0003 | -0,0022 |
| RMSSD HRV, msec | 1,688 | 1,349 | 1,380 | 0,098 | 0,078 | 0,080 |
| pNN ₅₀ HRV, % | -0,993 | -1,992 | -0,390 | -0,080 | -0,161 | -0,032 |
| Stange's test, sec | 0,027 | 0,318 | 0,089 | 0,002 | 0,020 | 0,006 |
| LFnu HRV, % | 0,518 | -0,598 | -0,303 | 0,031 | -0,036 | -0,018 |
| Potassium Serum, mM/L | 0,284 | -0,358 | 0,069 | 0,519 | -0,654 | 0,126 |
| Catalase, $\mu\text{M/L} \cdot \text{h}$ | -0,325 | 0,467 | 0,421 | -0,0064 | 0,0093 | 0,0084 |
| Creatininuria, mM/24h | 0,201 | -0,027 | -0,911 | 0,054 | -0,007 | -0,244 |
| Diuresis, L/24h | -0,453 | -0,305 | 0,548 | -0,727 | -0,489 | 0,878 |
| LF band HRV, msec ² | -1,070 | 0,360 | 1,423 | -0,0014 | 0,0005 | 0,0018 |
| Phosphates Serum, mM/L | -0,095 | 0,239 | 0,520 | -0,474 | 1,195 | 2,607 |
| Calcium Serum, mM/L | 0,204 | -0,259 | -0,007 | 1,161 | -1,470 | -0,039 |
| | | | Constants | 2,498 | -0,054 | 4,779 |
| | | | Eigenvalues | 13,70 | 4,147 | 0,487 |
| | | | Cumulative Proportions | 0,747 | 0,973 | 1 |

At the next stage of the analysis, the normalized values of the variables were grouped into three discriminant roots based on the structural coefficients (Table 5). In addition to discriminant variables, the table also presents variables that are not included in the model, but are still informal carriers of identifying information.

Table 5. Correlations of variables with canonical roots, root mean values and Z-values of variables

| Variables | Correlations | | | C++ (2/1) | C+ (16/2) | Cn (45/11) | C- (5/6) |
|------------------|-----------------|--------|--------|------------------|----------------|----------------|----------------|
| | Variables-Roots | | | | | | |
| Root 1 (74,6%) | R 1 | R 2 | R 3 | -17,0 | -2,5 | 1,2 | 2,9 |
| UA Clearance | -0,628 | -0,266 | 0,098 | 11,1±1,6 | $3,25\pm0,17$ | $-0,14\pm0,15$ | $-2,63\pm0,11$ |
| Uricosuria | -0,239 | -0,308 | 0,189 | 4,75±0,50 | $3,20\pm0,39$ | $0,76\pm0,19$ | $-1,35\pm0,15$ |
| Urea Excretion | | | | 4,75±1,00 | $2,97\pm0,62$ | $1,03\pm0,32$ | $-1,27\pm0,53$ |
| Diuresis | -0,130 | -0,163 | 0,144 | 3,82±0,18 | $2,92\pm0,39$ | $1,26\pm0,22$ | $0,04\pm0,53$ |
| Calciuria | | | | 4,11±1,28 | $1,99\pm0,77$ | $0,49\pm0,42$ | $-0,99\pm1,01$ |
| LF band HRV | -0,138 | -0,024 | -0,188 | 8,56±1,15 | $2,06\pm0,80$ | $0,45\pm0,29$ | $-0,43\pm0,40$ |
| Parathyroid horm | | | | 0,92±0,50 | $0,68\pm0,28$ | $-0,02\pm0,17$ | $-0,94\pm0,38$ |
| Total Power HRV | -0,090 | 0,018 | -0,171 | 4,51±1,28 | $0,50\pm0,47$ | $-0,01\pm0,26$ | $-0,10\pm0,38$ |
| VLF band HRV | -0,081 | 0,077 | -0,125 | 2,08±0,79 | $-0,15\pm0,25$ | $-0,25\pm0,14$ | $0,00\pm0,31$ |

| | | | | | | | |
|-----------------------------|---------------|---------------|---------------|-------------------|-------------------|-------------------|-------------------|
| pNN₅₀ HRV | -0,042 | -0,060 | -0,137 | 1,34±0,84 | 0,43±0,42 | 0,01±0,23 | -0,69±0,20 |
| RMSSD HRV | -0,043 | -0,024 | -0,059 | 1,35±0,77 | 0,42±0,46 | -0,22±0,13 | 0,14±0,39 |
| SDNN HRV | | | | 0,90±0,32 | -0,24±0,15 | -0,37±0,08 | -0,34±0,12 |
| TNN HRV | | | | 1,83±0,98 | -0,03±0,36 | -0,13±0,22 | -0,61±0,35 |
| LFnu band HRV | -0,042 | -0,038 | -0,112 | 1,31±0,39 | 0,61±0,32 | 0,57±0,17 | -0,06±0,40 |
| Lytogenicity Urine | -0,101 | -0,160 | 0,007 | 1,41±0,22 | 1,11±0,22 | 0,58±0,10 | -0,08±0,17 |
| Magnesiuria | | | | 1,91±0,79 | 1,29±0,43 | 0,37±0,25 | -0,36±0,49 |
| Urea Serum | -0,080 | -0,074 | -0,124 | 1,51±0,57 | 0,63±0,37 | 0,41±0,13 | -0,33±0,29 |
| BP diastolic | | | | 2,48±0,67 | 1,34±0,44 | 0,33±0,18 | 0,19±0,38 |
| Pd2/Pd1 Ratio | | | | 0,98±0,38 | 0,90±0,30 | 0,58±0,20 | 0,36±0,43 |
| Chloriduria | -0,073 | -0,062 | 0,055 | 5,16±1,69 | 3,31±0,80 | 1,84±0,43 | 0,65±1,21 |
| Natriuria | | | | 4,58±1,36 | 2,83±0,64 | 1,60±0,34 | 0,66±0,97 |
| Kaliuria | | | | 2,77±0,48 | 0,85±0,44 | 0,18±0,25 | 0,27±0,89 |
| Creatinineuria | -0,024 | -0,058 | -0,087 | -0,62±0,24 | -0,76±0,21 | -0,85±0,17 | -1,32±0,27 |
| Diene conjugates | | | | -0,14±0,01 | -0,44±0,07 | -0,73±0,04 | -0,75±0,14 |
| Uricemia | 0,147 | 0,105 | 0,063 | -1,89±0,32 | 0,30±0,26 | 1,31±0,19 | 2,94±0,37 |
| Catalase | 0,108 | 0,046 | -0,139 | -1,54±0,18 | -0,65±0,19 | -0,04±0,12 | 0,16±0,35 |
| Chloride Serum | | | | -4,13±1,20 | -0,63±0,46 | 0,42±0,26 | 1,34±0,48 |
| Sodium Serum | | | | -3,90±0,99 | -1,01±0,38 | -0,15±0,21 | 0,61±0,40 |
| Stange's test | 0,055 | 0,030 | 0,005 | -0,33±0,34 | 0,65±0,44 | 1,05±0,21 | 1,43±0,42 |
| ULF band HRV | 0,024 | 0,020 | 0,300 | -0,94±0,12 | -0,04±0,38 | -0,40±0,14 | 0,24±0,30 |
| Calcium Serum | 0,030 | 0,069 | 0,238 | -1,20±0,55 | -0,69±0,30 | -0,80±0,15 | 0,02±0,39 |
| Phosphates Serum | 0,019 | 0,083 | 0,229 | -1,07±0,54 | -0,92±0,23 | -1,02±0,17 | -0,29±0,40 |
| Calcitonin norm-d | 0,019 | 0,012 | 0,087 | -0,95±0,07 | -0,64±0,16 | -0,66±0,15 | -0,43±0,26 |
| Root 2 (22,6%) | R 1 | R 2 | R 3 | 4,2 | -2,3 | -0,3 | 4,2 |
| Phosphaturia | -0,053 | -0,139 | 0,090 | 0,30±0,99 | 0,92±0,49 | -0,30±0,29 | -1,50±0,38 |
| Potassium Serum | 0,013 | -0,101 | 0,089 | -1,28±0,80 | -0,10±0,24 | -0,42±0,16 | -0,78±0,37 |
| Aldosterone | | | | -0,15±0,14 | -0,46±0,14 | -0,30±0,11 | 0,04±0,12 |
| Root 3 (2,7%) | R 1 | R 2 | R 3 | -0,9 | 1,0 | -0,4 | 0,9 |
| Superoxidedismut | 0,062 | -0,012 | -0,295 | -0,50±0,24 | 0,08±0,34 | 0,92±0,17 | 0,43±0,51 |
| Ps2/Ps1 Ratio | | | | -1,72±0,82 | -1,08±0,31 | -0,24±0,25 | -0,56±0,18 |
| BP systolic | | | | 1,68±0,14 | 1,47±0,31 | 0,73±0,15 | 1,26±0,46 |
| Pd3/Pd1 Ratio | | | | 1,86±0,91 | 1,47±0,27 | 0,62±0,20 | 0,92±0,23 |






Fig. 7. Scattering of individual values of the discriminant roots of patients from different clusters of uric acid clearance

Localization of individual values of the first discriminant root visualizes abnormal deviations from the norm, along with clearance, uricosuria and uricemia by definition, a number of other metabolic and autonomic-endocrine parameters. Patients with a moderately urate-losing kidney are also moderately distant from patients with a euuricosic kidney, but their demarcation is clear. At the same time, patients with urate-retaining kidneys are not clearly demarcated.

However, these two clusters are clearly demarcated along the second root axis. The top position of patients with urate-retaining kidneys reflects their minimum levels of phosphaturia and kaliemia, as well as a normal, but maximum for the sample, aldosterone level. The lowest localization of patients with urate-losing kidney reflects their maximum phosphaturia and normal, but maximum for the sample, serum potassium level, as well as the lowest aldosterone level. Euuricose patients occupy an intermediate position.

Additional demarcation of patients with euuricosis occurs along the axis of the third root. Their lowest position reflects their highest SOD activity. Euuricosis is accompanied by a normal level of diastolic pressure and its reactions to occlusion during the triplex tensiometric test [32]. Instead, these parameters are higher/lower, respectively, in patients with clearance deviations from the norm.

In general, in the information space of the three roots, the demarcation of clusters is quite clear, which is documented by the calculation of Mahalanobis distances (Table 6).

Table 6. Mahalanobis distances between clusters, F-values (df=23,6) and p-levels

| Clusters | Cn | C+ | C- | C++ |
|------------|--|--|--|-----|
| Cn | 0 | 20 | 25 | 352 |
| C+ | 8,6 10^{-6} | 0 | 71 | 257 |
| C- | 7,4 10^{-6} | 15,6 10^{-6} | 0 | 399 |
| C++ | 32,2 10^{-6} | 21,2 10^{-6} | 30,2 10^{-6} | 0 |

With the help of classification functions coefficients and constants (Table 7), we will find out the possibility of identifying the belonging of this or that person to this or that cluster without errors.

Table 7. Coefficients and constants for cluster classification functions

| Clusters | Cn | C+ | C- | C++ |
|--|--------|--------|--------|---------|
| Variables | p=.636 | p=.205 | P=.125 | p=.034 |
| Uric Acid Clearence, mL/min | 4,789 | 7,379 | 6,977 | 32,138 |
| Uricosuria, mM/24 h | -16,08 | -16,73 | -23,93 | -61,45 |
| Uricemia, μM/L | 0,117 | 0,091 | 0,254 | 0,580 |
| Calcitonin normalized, Z | -2,393 | -4,710 | -1,025 | -14,543 |
| Lytogenicity urine | 74,17 | 74,53 | 62,85 | 118,6 |
| Phosphates Excretion, mM/24h | -0,764 | -0,649 | -0,843 | -0,392 |
| Urea Serum, mM/L | 11,85 | 12,47 | 8,650 | 7,853 |
| Superoxide dismutase, U/mL | 0,440 | 0,363 | 0,343 | -0,089 |
| VLF band HRV, msec² | -0,057 | -0,054 | -0,050 | -0,037 |
| Chloride Excretion mM/24h | 0,057 | 0,033 | 0,056 | -0,088 |
| ULF band HRV, msec² | -0,080 | -0,064 | -0,084 | -0,079 |
| Total Power HRV, msec² | 0,053 | 0,048 | 0,049 | 0,042 |
| RMSSD HRV, msec | 1,969 | 1,568 | 2,597 | 0,512 |
| pNN₅₀ HRV, % | -2,591 | -2,019 | -3,496 | -1,845 |
| Stange's test, sec | 0,725 | 0,687 | 0,825 | 0,781 |
| LFnu HRV, % | 1,394 | 1,326 | 1,260 | 0,676 |
| Potassium Serum, mM/L | 30,13 | 29,71 | 28,24 | 17,67 |
| Catalase, μM/L·h | -0,126 | -0,109 | -0,084 | 0,030 |
| Creatininuria, mM/24h | 1,615 | 1,082 | 1,331 | 0,704 |
| Diuresis, L/24h | 11,35 | 16,26 | 9,150 | 22,01 |
| LF band HRV, msec² | -0,074 | -0,067 | -0,071 | -0,047 |
| Phosphates Serum, mM/L | -16,26 | -13,17 | -8,021 | -3,272 |
| Calcium Serum, mM/L | 106,94 | 105,5 | 102,2 | 79,09 |
| Constants | -362,0 | -370,8 | -365,4 | -566,4 |

DISCUSSION

Urate handing in the human body is a complex system including three major processes: production, renal elimination, and intestinal elimination. A change in any one of these can affect both the steady-state serum urate concentration as well as other urate processes. The remarkable complexity underlying urate regulation and its maintenance at high levels in humans suggests that this molecule could potentially play an interesting role other than as a mere waste product to be eliminated as rapidly as possible. Urate is produced during the metabolism of endogenous (typically DNA and RNA) and exogenous (food-derived) purines. Once produced, urate cannot be further metabolized by human cells and so must be eliminated by either renal or extra-renal elimination routes [19]. The kidney excretes two-thirds of UA. Skin, nails, hair, saliva, and the gastrointestinal tract (GIT) eliminates the remaining third. In the GIT, bacteria convert part of the uric acid to ammonia and carbon dioxide, which is expelled as gas. Ammonia is either absorbed and excreted in the urine or utilized by bacteria as an energy source. The majority of serum UA (95%) is in the form of monosodium urate and is freely filtered at in the glomeruli, while the remaining is protein bound. Ninety-nine percent of the filtered urate is reabsorbed in the proximal convoluted tubule (PCT) through complex successive reabsorption, secretion, and again reabsorption and 50% is then secreted back into the PCT. Post secretory absorption of 80% of this urate occurs in the distal PCT. Therefore, about 10% of the filtered urate is excreted in the urine. The fractional excretion of urate ranges from 60% in a premature neonate, to 12% in a children and 7% in the adults [1].

The balance of production and elimination determines the concentration of urate in the circulation. Urate, with a pKa of 5.3, is also found in its deprotonated form uric acid; however,

uric acid represents only ~1% of the total urate in blood because of the pH. In urine, more of the urate is unprotonated uric acid due to the lower pH found in urine but at any urine pH above 5.3, more than half the molecule will be in the form of urate. Elevated serum urate (sUA) is the primary cause of gout, an inflammatory arthritis induced by monosodium urate crystals. Hyperuricemia is defined as sUA concentrations greater than 404 $\mu\text{mol/L}$, which is the in vitro solubility limit of monosodium urate. Gout occurs in patients with sUA above 404 $\mu\text{mol/L}$ and gout prevalence increases as sUA rises above the 404 $\mu\text{mol/L}$ threshold. International guidelines recommend lowering sUA levels to a target range of <360 $\mu\text{mol/L}$ in all gout case scenarios and below <300 $\mu\text{mol/L}$ in those with greater disease severity and urate burden, such as those with tophi. Therefore, clarity on the interplay between factors that affect serum urate handling is a key component to understanding and treating gout [19].

Elimination of urate occurs via two routes: renal elimination and extra-renal elimination. Urate elimination is a dynamic process mediated by multiple specific import and export transporters in the renal proximal tubule, salivary glands and the intestinal mucosa. The amount of urate excreted via these elimination routes can be quantified as clearance in milliliters per minute of serum (or blood) in the circulation that is cleared. Thus, the total clearance of urate is the sum of the renal clearance and the extra-renal clearance. The total rate of urate removed per minute is the product of the total clearance and the sUA concentration. So, at steady state, for a given rate of production, sUA will settle at a point at which total elimination is equal to production. These relationships form the basis for understanding the dynamics of urate concentration in the serum. The kidney is typically responsible for approximately 60–65% of daily urate elimination. Urate in blood is freely filtered in the kidney by the glomerulus. The filtered urate is subjected to significant reabsorption in the proximal tubule. In addition, secretion of urate also occurs. Both these processes are carried out by a series of membrane transporters. Of the filtered urate, only 3–10% is eventually excreted in the urine with the majority reabsorbed in the proximal tubule [19].

CONCLUSION

Constitutionally distinct types of uric acid metabolism (euricosis, urate losing and saving kidneys) are characterized by specific constellations of metabolic and autonomic-endocrine parameters. A detailed analysis of the mechanisms of such connections will be carried out in the next article.

ACKNOWLEDGMENT

We express sincere gratitude to colleagues from sanatorium “Moldova” for help in conducting this investigation.

ACCORDANCE TO ETHICS STANDARDS

Tests in patients are conducted in accordance with positions of Helsinki Declaration 1975, revised and complemented in 2002, and directive of National Committee on ethics of scientific researches. During realization of tests from all parent of participants the informed consent is got and used all measures for providing of anonymity of participants.

For all authors any conflict of interests is absent.

REFERENCES

1. Abou-Elela A. Epidemiology, pathophysiology, and management of uric acid urolithiasis: A narrative review. *J Adv Res.* 2017;8(5):513-527. doi: 10.1016/j.jare.2017.04.005.
2. Andreyeva LI, Kozhemyakin LA, Kishkun AA. Modification of the method for determining the lipid peroxide in the test with thiobarbituric acid [in Russian]. *Laboratornoye Delo.* 1988; 11: 41-43.
3. Biletsky SV & Gozhenko AI. Hypoxic-hypercapnic training in cardiology. Chernivtsi: 2007.
4. Bombushkar IS, Gozhenko AI, Badiuk NS, Smagliy SS, Korda MM, Popovych IL, Blavatska OM. Relationships between parameters of uric acid metabolism and neuro-endocrine factors of adaptation [in Ukrainian]. *Journal of marine medicine.* 2022; 2(95): 59-74.
5. Dubinina YY, Yefimova LF, Sofronova LN, Geronimus AL. Comparative analysis of the activity of superoxide dismutase and catalase of erythrocytes and whole blood from newborn children with chronic hypoxia [in Russian]. *Laboratornoye Delo.* 1988; 8: 16-19.
6. El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. *J Adv Res.* 2017; 8(5): 487-493.
7. Fedoruk AS, Gozhenko AI, Rohovyi YY. Protective effect of α -tocopherol on kidney function and lipid peroxidation in acute hemic hypoxia [in Russian]. *Patologicheskaya Fiziologiya.* 1998; 4: 35-38.
8. Flyunt VR, Flyunt I-SS, Fil' VM, Kovbasnyuk MM, Hryvnak RF, Popel SL, Zukow W. Relationships between caused by drinking of bioactive water Naftussya changes in urine lithogenicity and neuro-humoral-immune factors in humans with their abnormalities. *Journal of Education, Health and Sport.* 2017; 7(3): 11-30.
9. Gavrilov VB, Mishkorudnaya MI. Spectrophotometric determination of plasma levels of lipid hydroperoxides [in Russian]. *Laboratornoye Delo.* 1983; 3: 33-36.
10. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. *Curr Rheumatol Rep.* 2011;13(2):160-166.
11. Goryachkovskiy AM. Clinical Biochemistry [in Russian]. Odesa: Astroprint; 1998: 608
12. Gozhenko, A. (2016). Functional-metabolic continuum [in Russian]. *Journal of NAMS of Ukraine,* 22(1), 3-8.
13. Gozhenko AI, Biryukov V, Muszkieta R, Zukow W. Physiological basis of human longevity: the concept of a cascade of human aging mechanism. *Coll Antropol.* 2018; 42(2): 139-146.
14. Gozhenko AI, Dorenskiy VS, Rudina YI, Rasputniak G, Kotyuzhinskaya SG, Kotyuzhinskiy AL, Slavina LG. Causes and mechanisms of intoxication with nitrates and nitrites [in Russian]. *Meditina Truda I Promyshlennaya Ekologiya.* 1995; 4: 15-20.
15. Gozhenko AI, Korda MM, Popadynets' OO, Popovych IL. Entropy, Harmony, Synchronization and Their Neuro-Endocrine-Immune Correlates [in Ukrainian]. Odesa. Feniks; 2021: 232.
16. Gozhenko AI & Kotyuzhinskaya SG. Changes in kidney function during acute intoxication with sodium nitrite in an experiment [in Russian]. *Patologicheskaya Fiziologiya.* 2003; 1: 28-30.
17. Gozhenko A, Zantaraia T, Zukow W. „Falling values”: artifacts or source of unique information? Drastically low electrical conductivity of acupuncture points is accompanied by significant deviations of EEG, HRV, immunity, metabolism and GDV parameters. *Quality in Sport.* 2024; 17:51006. dx.doi.org/10.12775/QS.2024.17.004
18. Hozhenko AI, Kravchuk AV, Nikitenko OP, Moskalenko OM, Sirman VM. Funktsional'nyi nyrkovyi rezerv. Functional renal reserve [in Ukrainian]. Odesa: Feniks; 2015: 180.
19. Hyndman D, Liu S, Miner JN. Urate Handling in the Human Body. *Curr Rheumatol Rep.* 2016;18(6):34. doi: 10.1007/s11926-016-0587-7.
20. Ivassivka SV, Popovych IL, Aksentiychuk BI, Flyunt IS. Physiological Activity of Uric Acid and its Role in the Mechanism of Action of Naftussya Water [in Ukrainian]. Kyiv: Computerpress; 2004: 163.
21. Karve MD, Katysheva OV, Ankhimiuk ON, et al. The value of blood uric acid according to a clinical and epidemiological study [in Russian]. *Voprosy Okhrany Materinstva I Detstva.* 1989; 34(4): 22-27.
22. Khmelevskyi YV & Usatenko OK. Basic Biochemical Constants of Humans at Norm and at Pathology [in Russian]. Kyiv: Zdorovya; 1987: 160.

23. Klecka WR. Discriminant Analysis [trans. from English in Russian] (Seventh Printing, 1986). In: Factor, Discriminant and Cluster Analysis. Moskva: Finansy i Statistika; 1989: 78-138.

24. Korda MM, Gozhenko AI, Popovych IL, Klishch IM, Bombushkar IS, Korda IV, Badiuk NS, Zukow WA, Smagliy VS. Neurotropic, Hormonal and Immunotropic Activity of Uric Acid. Monograph. Ternopil': Ukrmedknyha; 2024:206. <https://doi.org/10.5281/zenodo.10990426>

25. Korolyuk MA, Ivanova MI, Mayorova IG, Tokarev VYe. The method for determining the activity of catalase [in Russian]. Laboratornoye Delo. 1988; 1: 16-19.

26. Makarenko YeV. A comprehensive definition of the activity of superoxide dismutase and glutathione reductase in red blood cells in patients with chronic liver disease [in Russian]. Laboratornoye Delo. 1988; 11: 48-50.

27. Morelli M, Carta AR, Kachroo A, Schwarzschild A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010; 183: 183-208.

28. Lukovych YuS., Popovych AI, Kovbasnyuk MM, Korolyshyn TA, Barylyak LG, Popovych IL. Neuroendocrine and immune support of the diuretic effect of balneotherapy at the Truskavets resort [in Ukrainian]. Kidneys. 2015; 2(12): 7-14.

29. Park JH, Jo YI, Lee JH. Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med. 2020;35(6):1291-1304. doi: 10.3904/kjim.2020.410.

30. Polovynko IS, Zajats LM, Zukow W, Yanchij RI, Popovych IL. Quantitative evaluation of integrated neuroendocrine and immune responses to chronic stress in rat male. Journal of Education, Health and Sport. 2016; 6(8):154-166.

31. Popovych IL, Gozhenko AI, Korda MM, Klishch IM, Popovych DV, Zukow W (editors). Mineral Waters, Metabolism, Neuro-Endocrine-Immune Complex. Odesa. Feniks; 2022: 252.

32. Popovych IL, Kozyavkina NV, Barylyak LG, Vovchyna YV, Voronych-Semchenko NM, Zukow W, Tsymbryla VV. Variants of changes in blood pressure during its three consecutive registrations. Journal of Education, Health and Sport. 2022;12(4):365-375.

33. Tiselius HS. A biochemical basis for grouping of patients with urolithiasis. Europ Urol. 1978; 4: 241-249.

34. Žukow X & Zavidnyuk YV. Glomerular filtration and diuresis are related to the state of lipids peroxidation in female rats exposed to water-salt loads accompanied by chronic stress. Journal of Education, Health and Sport. 2021;11(12):481-491. <http://dx.doi.org/10.12775/JEHS.2021.11.12.039>